Literature DB >> 19402803

NICE at 10 years: new challenges ahead.

Peter Littlejohns1.   

Abstract

NICE has existed for 10 years. During this period, its methodological approach to developing guidance and assessing the value (cost-effectiveness) of healthcare interventions has received considerable national and international interest. At the same time, individual decisions have generated enormous controversy. This 10th anniversary provides an opportunity to look back at how the institute has responded and adapted to the various challenges and controversies. Following Lord Darzi's review of the National Health Service (UK) in 2008, the institute took on further responsibilities for setting clinical standards for the National Health Service. This article explores these developments and speculates on future trends.

Mesh:

Year:  2009        PMID: 19402803     DOI: 10.1586/erp.09.13

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  1 in total

Review 1.  Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authorities.

Authors:  Francesco Pignatti; Bertil Jonsson; Gideon Blumenthal; Robert Justice
Journal:  Mol Oncol       Date:  2014-10-16       Impact factor: 6.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.